Hormonal
Sleeve gastrectomy (SG) induces metabolic changes beyond restriction by reducing ghrelin and increasing GLP-1 and GIP, which stimulates insulin release and delays gastric emptying to improve type 2 diabetes.
If you undergo sleeve gastrectomy, your body's hormone production changes to help control blood sugar and hunger, not just because your stomach is smaller. This metabolic shift is a key reason why type 2 diabetes often improves after this specific surgery.
After (SG) serum ghrelin, a hormone that increases hunger is reduced, and gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) production are increased [27]. These changes stimulate insulin release, delay gastric emptying, and induce satiety, resulting in decreased blood glucose levels in individuals with type 2 diabetes [27].
Why this rating
The paper cites specific studies ([27]) and describes a clear physiological pathway, though it is a position statement summarizing literature.
Source
Metabolic/bariatric surgery optimization: a position statement by Arabic association for the study of diabetes and metabolism (AASD)
Amin Roshdy Soliman et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-024-01564-w
More from this paper
- GLP-1 receptor agonists (semaglutide and tirzepatide) are effective treatments for weight regain after bariatric surgery, producing clinically significant weight loss without severe adverse events.Good
- Sleeve gastrectomy is associated with a higher risk of new-onset or worsening gastroesophageal reflux disease (GERD) compared to Roux-en-Y gastric bypass (RYGB).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →